| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Collaboration revenue | 1,248 | 8,659 | 8,513 | 4,127 |
| Research and development | 19,300 | 25,283 | 22,507 | 25,142 |
| General and administrative | 6,535 | 6,215 | 6,993 | 6,805 |
| Total operating expenses | 25,835 | 31,498 | 29,500 | 31,947 |
| Loss from operations | -24,587 | -22,839 | -20,987 | -27,820 |
| Interest income | 1,539 | 2,214 | 2,485 | 2,887 |
| Change in fair value of long-term investments | NaN | 0 | 1,292 | NaN |
| Other expense, net | -1 | -2 | -70 | -8 |
| Total other income, net | 1,538 | 2,212 | 1,123 | 2,879 |
| Net loss before provision for income taxes | -23,049 | -20,627 | -19,864 | -24,941 |
| Provision for income taxes | 10 | -234 | 44 | 98 |
| Net loss | -23,059 | -20,393 | -19,908 | -25,039 |
| Unrealized loss on available-for-sale marketable securities | -304 | -1 | -249 | -88 |
| Comprehensive loss | -23,363 | -20,394 | -20,157 | -25,127 |
| Basic EPS | -0.61 | -0.55 | -0.54 | -0.68 |
| Diluted EPS | -0.61 | -0.55 | -0.54 | -0.68 |
| Basic Average Shares | 37,581,094 | 37,349,449 | 37,156,979 | 37,019,027 |
| Diluted Average Shares | 37,581,094 | 37,349,449 | 37,156,979 | 37,019,027 |
Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics, Inc. (MGX)